PRESENTATION
SMC Laboratories is highly regarded worldwide as a consulting CRO that designs studies in line with the demands of pharmaceutical companies and research institutions.
In particular, in the NASH-HCC field, SMC is a highly regarded CRO, because of our unique STAM™ mice.
The results achieved with our STAM™ have been introduced in academic publications as well as scientific conferences.
Presentations
2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 3000
No.19
15th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV,
“Anti-fibrotic and anti-inflammatory activity of the dual CCR2 and CCR5 antagonist cenicriviroc in a mouse model of NASH” Tobira Therapeutics Inc.
No.18
AASLD 2013,
“Anti-fibrotic and anti-inflammatory activity of the dual CCR2 and CCR5 antagonist cenicriviroc in a mouse model of NASH” Tobira Therapeutics Inc.
No.17
AASLD 2013,
“L-carnitine prevents progression of non-alcoholic steatohepatitis with regulation of mitochondrial β-oxidation and redox system in NASH model Mice” Okayama University
No.16
FASEB SRC 2013, Lysophospholipid and Other Related Mediators – From Bench to Clinic,
“ATX inhibition prevents progression of non-alcoholic steatohepatitis (NASH) in a hypoinsulinemic mouse model of progressive liver disease” F. Hoffmann-La Roche, Ltd
No.15
DDW 2013,
“Vitamin E and L-Carnitine Prevents Progression of Non-Alcoholic Steatohepatitis With Regulation of Intestinal Inflammasome Activation in NASH Model Mice” Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
No.14
DDW 2013,
“Rosuvastatin Prevents Liver Tumorigenesis in High-Fat Diet-Fed Mice“ 2nd Department of Internal Medicine Osaka Medical College